Certificate of Analysis

Report GSA-COA-000078-TZP20-20261030-9
Issued 2026-11-04 · Page 1 of 2

Scan to verify

Tirzepatide 20 mg

Order GSA-2026-000078 · 6A Labs · 3 vials of one product

Customer	6A Labs
Order	GSA-2026-000078
Label	Tirzepatide 20 mg
Vials tested	3 (A2, B2, C2)
Prepared	29 Oct 2026
Tested	30 Oct 2026, 02 Nov 2026
Tests	Identity, Purity, Content, Impurities, Conformity

IDENTITY

Tirzepatide


confirmed in all 3 vials

PURITY


99.9 %

mean of 3 vials (99.9-100.0 %)

HPLC chromatograms (UV, 214 nm), every vial



Mass spectrum of the main peak, vial A2 (9.66 min)



Results by vial

Vial	Identity	Purity (214 nm)
Vial A2	Confirmed	100.00 %
Vial B2	Confirmed	99.87 %
Vial C2	Confirmed	99.89 %
Average		**99.92 %**
Difference		**0.13 points**

Difference = largest minus smallest vial. Purity is a share of the UV peak area.

APPROVED FOR RELEASE

Ian Ebert, Laboratory Director

Signed electronically
5 Nov 2026, 04:46 UTC
Release record: last page

Results are not covered by ISO/IEC 17025 accreditation.
Results relate only to the sample as received and tested.

Results

Identity	**Identified as tirzepatide in every vial.** Measured mass 4813.1, 4813.3, 4813.3 (average 4813.2; expected 4813.5); retention time matching the tirzepatide reference standard (9.67 min).
Purity	**99.92 %** (mean of 3 vials; 99.87-100.00 %) by HPLC with UV detection at 214 nm.
Conformity between vials	**Consistent.** The same peptide is the main compound of every vial (tirzepatide); Content of every vial within +/- 5 % of the three-vial mean; Purity of every vial within +/- 0.5 percentage points of the mean; Same impurity profile: no impurity of 0.3 % or more in one vial only: met. Criteria are the laboratory's batch-consistency limits for 3 vials; a formal content-uniformity test (USP <905>) needs 10 units.

Impurities

Every peak other than tirzepatide found in the vials, as a share of the UV peak area at 214 nm:

Peak (min)	Vial A2	Vial B2	Vial C2	Mean	What it is
2.75	-	0.11 %	0.02 %	0.04 %	A small unidentified peak (too small for its mass to be measured).


Trace peaks below 0.10 % add up to 0.00 % (vial A2), 0.02 % (vial B2), 0.09 % (vial C2). '-' = not found in that vial.


Net content

Vial	Net content	% of label
Vial A2	18.9 mg	94.6 %
Vial B2	19.3 mg	96.7 %
Vial C2	19.5 mg	97.4 %
Average	19.3 mg	96.3 %
Difference	0.57 mg (RSD 1.6 %)	2.9 points

Content is the mean of every injection of the vial's solution. Difference = largest minus smallest vial.

Zoomed views





Chain of custody

Receipt photograph of the vials: 29 Oct 2026 12:09, blue cap (TZ 20 mg). Sample preparation was video-recorded on 29 Oct 2026 (4 recordings, each identified by its SHA-256 fingerprint): 1,tz 20mg.mp4 (32 s, 083a5f2a22e24b1720804af49a739b5eea302d69ecb55bed37099ea5fd6b583c); 2 tz 20mg.mp4 (35 s, 5ae5238af0868a7b7ebc88d081a866e551a1cd36c73a97186ca81fec18a608af); 3 tz 20mg.mp4 (32 s, 1ef5dbb59b955f1efe331b8b9122a8f35279e8ca5d868e91e21eb74a1ce73f1f); 20mg tz pt2.mp4 (130 s, 52904ae7ca7f805ff36f3355f248a7b05ef934c1d141db2ce28c91fbcdb78a47).

How it was tested

Liquid chromatography with UV and mass-spectrometry detection: Agilent 1290 Infinity II LC with a 6490 triple-quadrupole mass spectrometer. Column Polaris C18-A, 2.0 x 150 mm, 55 °C; water and acetonitrile, each with 0.1 % formic acid. Purity: UV peak area at 214 nm. Identity: molecular mass and retention time against a reference standard. Content: UV at 220 nm against a tirzepatide reference standard; the whole vial was dissolved. Each vial was made up to 1 mg/mL from its label claim in 20 % acetonitrile / 80 % water with 0.1 % formic acid.

Notes

Results apply only to the vials as received and tested. Purity is a share of the UV peak area, not a weight percentage. Identity is by molecular mass and retention time; the amino-acid sequence was not checked.

APPROVED FOR RELEASE

Signed electronically by a Gold Standard Analytics lab technician at release.
The signature is at the bottom of page 1; the release record, the last page of this certificate, gives the date and verification code.

Gold Standard Analytics

goldstandardanalytics.com

Release record

Report GSA-COA-000078-TZP20-20261030-9 · Certificate GSA-2026-778817

Customer and order	6A Labs · GSA-2026-000078
Sample and report	078-TZP20 · Tirzepatide 20 mg Certificate of Analysis
Report reference	GSA-COA-000078-TZP20-20261030-9
Certificate accession	GSA-2026-778817
Released and signed by	Ian Ebert, Laboratory Director
Date and time (UTC)	2026-11-05 04:46:16Z
Signature meaning	Approved for release. The signer reviewed this report and approved its release to its customer.
Approval reference	4686f198-3176-4032-ba57-ff19f4f59d33
Electronic signature	Signed electronically in a signed-in GSA staff account.
Original report SHA-256	b23b7877333c40ae6700447b6308f7fbc3d141aa3ba7ed3394d19fecfd414bda
Verify this certificate	https://goldstandardanalytics.com/coa/GSA-2026-778817

Scan to view this certificate online

Signature



Ian Ebert, Laboratory Director

Results are not covered by ISO/IEC 17025 accreditation. Development method; not validated.
Results relate only to the sample as received and tested.